Background
Following the sudden and unexpected outbreak of SARS-CoV-2 in Wuhan, China, in December 2019, and its rapid spread around the world, on March 11, 2020, the WHO declared the SARS-CoV-2 a global pandemic and attempted to mobilize all available resources to combat this pandemic.1
However, given the very rapid expansion of the illness and its unique and disproportionately severe presentation, this new pandemic has led to a major global health crisis and has caused the death of more than 1.53 million people since its emergence.2 3 (As of the date of this paper, April 4, 2021, this number is now in excess of 2.8 million people.) There is no definitive treatment, and despite the discovery of the vaccine, its availability, distribution and universal access remain a challenge.4 To this end, early detection and strict isolation play an essential role in decreasing the transmission rate, leading to better management of healthcare resources, and improvavailability of treatment facilities for critically ill patients and personal protective equipment (PPE).5
This global pandemic has severely strained healthcare resources, and shortages of various types, such as hospital beds, PPE, skilled healthcare workers, etc, have further complicated this global crisis. One of the proposed mechanisms for slowing the pandemic and limiting the number of infected individuals has been widespread community testing and isolating infected individuals. Unfortunately, in under-resourced countries, which account for the vast majority of the world, widespread testing has not been available, so those countries have resorted to testing only those individuals who are clinically symptomatic. This presents a particular problem since a significant number of carriers of the disease may be asymptomatic. Thus, early identification of both symptomatic patients, as well as asymptomatic carriers, remains a challenge and, if overcome, may help in slowing the pandemic significantly, leading further to the more effective management of SARS-CoV-2 on a global scale.
In this regard, the triage protocol for trauma patients has been particularly problematic. Before the SARS-CoV-2 outbreak, the trauma triage protocol was relatively uncomplicated and focused solely on treating life-threatening injuries in the shortest possible time. However, the SARS-CoV-2 outbreak and the presence of asymptomatic carriers poses a new and uncontested challenge regarding their triage and the protection of healthcare staff and other trauma patients. So far, the question of the potential triage of a trauma patient with an unknown SARS-CoV-2 status remains unanswered.
Currently, reverse transcription-polymerase chain reaction (RT-PCR) seems to be the most widely used serological test in most healthcare systems to confirm the diagnosis in people with suspected COVID-19 infection. The diagnosis of suspected patients is based on the history of clinical symptoms associated with the disease and epidemiological history. The WHO has identified the presence of fever with symptoms of acute respiratory infection in a patient with close contact with a confirmed patient, or a history of traveling to endemic areas within 2 weeks before the onset of symptoms, as diagnostic criteria for a suspected patient.6 Other healthcare organizations in different countries have characterized suspicious patients, with some modification in the above definition. The Iranian Ministry of Health and Medical Education (MOHME) has defined the ‘suspected patient’ as someone with acute respiratory symptoms along with a history of close contact with a confirmed patient or travel to endemic areas within the previous 2 weeks. The presence of a fever is not a mandatory symptom in this definition.7 According to the European Centres for Disease Control (ECDC), the presence of fever or respiratory symptoms or impaired sense of smell and taste is sufficient to diagnose the possibility of the disease, as shown in table 1.8
The other modality of para-clinical investigation, which has been widely used as an adjunct diagnostic tool for SARS-CoV-2, is the chest CT. The presence of ground-glass opacity on chest CT within the clinical context has been used to confirm the diagnosis of SARS-CoV-2. While the chest CT findings do not necessarily associate with the clinical status of the SARS-CoV-2 patients, another complication in this regard is the utility of the chest CT for the diagnosis of SARS-CoV-2 among trauma patients, given that often trauma patients suffer from pulmonary contusion and potential ground-glass opacities on their chest CT, which may be secondary to their lung trauma and not their SARS-CoV-2 infection.9
The effective management of trauma patients with potential COVID-19 infection may be complicated by a number of other potential factors, including unstable clinical conditions, the presence of brain injury and decreased level of consciousness,5–7 the presence of fever secondary to trauma, the rise in inflammatory markers as well as leukocytosis secondary to trauma, and the impracticality of obtaining an accurate clinical history, along with clinical symptoms such as pulmonary contusion. Taken together, the use of available triage systems as well as diagnostic methods, whether case definition, certain laboratory findings or chest CT, etc, do not seem to fully apply to trauma patients. Furthermore, the asymptomatic carriers of SARS-CoV-2 pose a major challenge given that there is no established protocol for evaluating these patients in trauma centers.10 11
Given the significant limitations of global healthcare resources as well as the difficulties mentioned above and the shortcomings in available triage protocols, as they relate to trauma patients, we set out in this study to compare the available triage methods and also to establish a novel triage system which could prove to be more accurate and resource effective.